Pharmaron, I-Mab and Burning Rock Get Investor Validation From MSCI
Three up-and-coming Chinese pharma companies are among those included in latest adjustment for the index compiler’s China All Shares Index Key takeaways: MSCI’s addition of Pharmaron, I-Mab and Burning Rock…
RELATED ARTICLES
-
Sinking Burning Rock faces de-listing. But could privatization bid come first?
BNR.US
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Inaugural operating profit fails to lift 111 Inc.
YI.US
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
Discover hidden China stock gems in our weekly newsletter